Overview

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Status:
Completed
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clearside Biomedical, Inc.
Treatments:
Aflibercept
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide